Cancer News and Research

Latest Cancer News and Research

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

Study finds novel physical mechanism behind cancer migration

Ninety percent of cancer deaths resulted from metastasis, the spread of cancer to different areas in the body, yet scientific exploration of the possible mechanical factors that promote metastasis has been limited.

23 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

SCCA, ProCure to open new proton therapy center for cancer treatment

Seattle Cancer Care Alliance, together with ProCure Treatment Centers Inc., today held its ceremonial groundbreaking on a new proton therapy center in north Seattle that will provide a first-of-its-kind treatment option for cancer patients throughout the Northwest.

23 Mar 2011

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

23 Mar 2011

Biologists decipher molecular code regulating availability of brain channel linked to neuronal excitability

A key question in protein biochemistry is how proteins recognize "correct" interaction partners in a sea of cellular factors. Nowhere is that more critical to know than in the brain, where interactions governing channel protein activity can alter an organism's behavior.

23 Mar 2011

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

Dorothy Stockstill was taking eight pills a day, and her severe abdominal pain and persistent diarrhea weren't improving. The Denton resident had seen multiple physicians throughout the Dallas area. Her attacks were so severe, she couldn't successfully travel from the front of a retail store to the restrooms in back.

23 Mar 2011

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Asuragen, Inc. announced that they have achieved CE-marking and commercial launch in Europe of the AmplideX FMR1 PCR Kit for the detection of CGG repeats in the fragile X mental retardation gene.

23 Mar 2011

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Alterations in blood vessel dilation lie at the heart of coronary artery health: When vessels dilate, blood and oxygen supplies successfully reach the heart. When vessels contract, blood and oxygen are diminished, leading to coronary artery disease.

23 Mar 2011

Bowel cancer rate increases to 12% in over 60s in England due to screening test

Bowel cancer rates in 60 to 69 year olds went up by more than 12 per cent in England from 2006 to 2008, according to the latest figures from Cancer Research UK.

23 Mar 2011

New study to assess burden of workplace cancer

To date, there have been no comprehensive studies that have attempted to estimate how many work-related cancers occur in Ontario or Canada-wide. On March 23, 2011 the Occupational Cancer Research Centre (OCRC) is holding a symposium on assessing the human impact of workplace cancer.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN® (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

23 Mar 2011

Study finds IL-13 stimulates airway fibroblast invasion in asthma patients

Changes that occur in the airways of asthma patients are in part caused by the naturally occurring protein interleukin-13 which stimulates invasion of airway cells called fibroblasts, according to a study conducted by researchers at Duke University.

23 Mar 2011

Medical oncologist to receive AACR award for breast cancer research

Vassiliki Karantza, MD, PhD, a medical oncologist at The Cancer Institute of New Jersey will be honored with the Genentech BioOncology Career Development Award sponsored by the American Association for Cancer Research at the Association's 102nd Annual Meeting taking place April 2 through 6 in Orlando.

23 Mar 2011

Researchers discover novel gene regulation mechanism that contributes to HCC development

Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011